PMID- 32922505
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Yiqi Fumai Injection as an Adjuvant Therapy in Treating Chronic Heart Failure: A 
      Meta-Analysis of 33 Randomized Controlled Trials.
PG  - 1876080
LID - 10.1155/2020/1876080 [doi]
LID - 1876080
AB  - BACKGROUND: Yiqi Fumai injection (YQFM) is a traditional Chinese medicine widely 
      used for cardiovascular diseases in China. This systematic review aimed to 
      evaluate whether YQFM could be an effective and safe complementary therapy for 
      chronic heart failure (CHF). METHODS: Eight electronic literature databases were 
      searched up to March 31, 2020. Randomized controlled trials (RCTs) comparing 
      YQFM + conventional treatment with conventional treatment alone for CHF were 
      included. The primary outcome was response to treatment, which was graded by 
      improvements in heart function based on the New York Heart Association (NYHA) 
      criteria, while the secondary outcomes included the left ventricular ejection 
      fraction (LVEF), cardiac output, left ventricular end-systolic diameter (LVESD), 
      amino-terminal pro-brain natriuretic peptide (NT-proBNP), 6-minute walk test 
      performance (6MWT), quality of life (QoL) as assessed by the Minnesota Living 
      with Heart Failure questionnaire, and adverse reactions. Data from individual 
      RCTs were pooled by a random-effects meta-analysis with effect measures of 
      proportional odds ratios (pORs) and 95% confidence intervals (95% CIs) for the 
      ordinal outcomes and the mean difference (MD) and 95% CI for the continuous 
      outcomes. RESULTS: In total, 33 RCTs involving 3070 patients with an overall 
      moderate-to-high risk of bias were selected. The meta-analysis showed that 
      compared with conventional treatment alone, YQFM plus conventional treatment had 
      a significantly higher likelihood of improving the response to treatment (pOR 
      1.88, 95% CI 1.47 to 2.42, I (2) = 0%). YQFM also significantly improved the LVEF 
      (MD 5.53%, 95% CI 4.73 to 6.33, I (2) = 82%), cardiac output (MD 0.32 L/min, 95% 
      CI 0.19 to 0.45, I (2) = 47%), and LVESD (MD -3.73 mm, 95% CI -5.51 to -1.95, I 
      (2) = 22%), reduced the NT-proBNP levels (MD -341.83 pg/mL, 95% CI -417.89 to 
      -265.77, I (2) = 88%), and improved the 6MWT (MD 61.86 m, 95% CI 45.05 to 78.67, 
      I (2) = 64%) and QoL (MD -9.82, 95% CI -14.17 to -5.46, I (2) = 81%). No serious 
      adverse events related to YQFM were reported. CONCLUSION: Although limited by a 
      moderate-to-high risk of bias, the current evidence suggests that YQFM as a 
      complementary treatment significantly improves heart function and related 
      indicators in patients with CHF. The clinical use of YQFM needs careful safety 
      monitoring. Well-designed studies are still required to further evaluate the 
      efficacy and safety of YQFM for CHF.
CI  - Copyright (c) 2020 Heyun Nie et al.
FAU - Nie, Heyun
AU  - Nie H
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional 
      Chinese Medicine, Nanchang, Jiangxi, China.
FAU - Li, Shuqing
AU  - Li S
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional 
      Chinese Medicine, Nanchang, Jiangxi, China.
FAU - Liu, Meilu
AU  - Liu M
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional 
      Chinese Medicine, Nanchang, Jiangxi, China.
FAU - Zhu, Weifeng
AU  - Zhu W
AUID- ORCID: 0000-0003-0679-0691
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional 
      Chinese Medicine, Nanchang, Jiangxi, China.
FAU - Zhou, Xu
AU  - Zhou X
AUID- ORCID: 0000-0002-9541-4796
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional 
      Chinese Medicine, Nanchang, Jiangxi, China.
FAU - Yan, Dongmei
AU  - Yan D
AUID- ORCID: 0000-0003-3652-4394
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional 
      Chinese Medicine, Nanchang, Jiangxi, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200819
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7453275
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
PMCR- 2020/08/19
CRDT- 2020/09/14 05:51
PHST- 2020/05/16 00:00 [received]
PHST- 2020/07/07 00:00 [revised]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/09/14 05:51 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
PHST- 2020/08/19 00:00 [pmc-release]
AID - 10.1155/2020/1876080 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Aug 19;2020:1876080. doi: 
      10.1155/2020/1876080. eCollection 2020.